Regulatory approval of new medicines requires a thorough assessment of the potential clinical benefits and risks. Study end-points are expected to demonstrate a clinically relevant treatment effect that will translate into direct patient benefits. This study sought to review the ophthalmic medicines with European Union–wide approval granted via the Centralised Procedure and characterise the key efficacy end-points underpinning the demonstration of clinical benefit.
Methods:
This study was a retrospective review of published data pertaining to the European regulatory authorisation of centrally approved ophthalmic products between 1999 and 2017, inclusive. All sources and data consulted are in the public domain. European Public Assessment Reports published by the European Medicines Agency were consulted for data concerning the pivotal clinical efficacy studies supporting the applications. Data analyses were descriptive.
Results:
The European Medicines Agency have authorised 30 products via the Centralised Procedure between 1999 and 2017. For these products, a total of 24 additional approvals for line extensions or additional therapeutic indications were granted. Four products have been approved for orphan indications, including one approval ‘under exceptional circumstances’ and one ‘Conditional Marketing Authorisation’. Approvals for products in retina (36%) and glaucoma (28%) indications together accounted for the majority of authorisations, with trial end-points predominantly based on visual acuity and intraocular pressure parameters, respectively. Products were also approved for indications in ocular surface disease, inflammation, optic neuropathy and surgical adjuncts, with a range of functional and anatomical end-points.
Conclusion:
Approvals for ophthalmic medicines have been granted for a range of clinical indications, representing a considerable portion of available major therapeutics for practitioners. Benefit–risk assessments rely on clinical trial data demonstrating a clearly relevant patient benefit.
European Parliament and Council of European Union. Council directive 2001/83/EC on the community code relating to medicinal products for human use. J Eur Union2001; 311: 67–128.
2.
European Parliament and Council of European Union. Regulation (EC) No 726/2004 of the European Parliament and of the Council laying down community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. J Eur Union2004; 136: 1–33.
3.
European Medicines Agency. EU regulatory workshop – ophthalmology – summary and report. Report no. EMA/450332/2012, 31August2012. London: European Medicines Agency.
4.
GreenEYothersGSargentDJ.Surrogate endpoint validation: statistical elegance versus clinical relevance. Stat Methods Med Res2008; 17(5): 477–486.
5.
WickstromKMoseleyJ.Biomarkers and surrogate endpoints in drug development: a European regulatory view. Invest Ophthalmol Vis Sci2017; 58(6): BIO27–BIO33.
QuigleyHABromanAT.The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol2006; 90(3): 262–267.
9.
ProkofyevaEZrennerE.Epidemiology of major eye diseases leading to blindness in Europe: a literature review. Ophthalmic Res2012; 47(4): 171–188.
10.
European Medicines Agency: Science Medicine Health. Points to consider on application with 1. meta-analyses; 2. one pivotal study. Report no. CPMP/EWP/2330/99, 31May2001. London: European Medicines Agency.
11.
TahVOrlansHOHyerJ, et al. Anti-VEGF therapy and the retina: an update. J Ophthalmol2015; 2015: 627674.
12.
BrandCS.Management of retinal vascular diseases: a patient-centric approach. Eye (Lond)2012; 26(Suppl. 2): S1–S16.
13.
AgarwalARhoadesWRHanoutM, et al. Management of neovascular age-related macular degeneration: current state-of-the-art care for optimizing visual outcomes and therapies in development. Clin Ophthalmol2015; 9: 1001–1015.
14.
StuartAFordJADuckworthS, et al. Anti-VEGF therapies in the treatment of choroidal neovascularisation secondary to non-age-related macular degeneration: a systematic review. BMJ Open2015; 5(4): e007746.
15.
EsmailiDDBoyerDS.Recent advances in understanding and managing retinal vein occlusions. F1000res2018; 7: 467.
16.
SnapinnSMJiangQ.Responder analyses and the assessment of a clinically relevant treatment effect. Trials2007; 8: 31.
17.
SaddaSRChakravarthyUBirchDG, et al. Clinical endpoints for the study of geographic atrophy secondary to age-related macular degeneration. Retina2016; 36(10): 1806–1822.
18.
SchaalKBRosenfeldPJGregoriG, et al. Anatomic clinical trial endpoints for nonexudative age-related macular degeneration. Ophthalmology2016; 123(5): 1060–1079.
19.
HolzFGStraussECSchmitz-ValckenbergS, et al. Geographic atrophy: clinical features and potential therapeutic approaches. Ophthalmology2014; 121(5): 1079–1091.
20.
CocceKJStinnettSSLuhmannUFO, et al. Visual function metrics in early and intermediate dry age-related macular degeneration for use as clinical trial endpoints. Am J Ophthalmol2018; 189: 127–138.
21.
FerraraDSilverRELouzadaRN, et al. Optical coherence tomography features preceding the onset of advanced age-related macular degeneration. Invest Ophthalmol Vis Sci2017; 58(9): 3519–3529.
22.
MidenaEPilottoE.Microperimetry in age: related macular degeneration. Eye (Lond)2017; 31(7): 985–994.
23.
PhadikarPSaxenaSRuiaS, et al. The potential of spectral domain optical coherence tomography imaging based retinal biomarkers. Int J Retina Vitreous2017; 3: 1.
24.
WongENDe SoyzaJDAMackeyDA, et al. Intersession test-retest variability of microperimetry in type 2 macular telangiectasia. Transl Vis Sci Technol2017; 6(6): 7.
25.
RamachandranRCaiCXLeeD, et al. Reliability of a manual procedure for marking the EZ endpoint location in patients with retinitis pigmentosa. Transl Vis Sci Technol2016; 5(3): 6.
26.
MooreNAMorralNCiullaTA, et al. Gene therapy for inherited retinal and optic nerve degenerations. Expert Opin Biol Ther2018; 18(1): 37–49.
27.
CsakyKFerrisFIIIChewEY, et al. Report from the NEI/FDA endpoints workshop on age-related macular degeneration and inherited retinal diseases. Invest Ophthalmol Vis Sci2017; 58(9): 3456–3463.
28.
HeijlALeskeMCBengtssonB, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol2002; 120(10): 1268–1279.
29.
Garway-HeathDFCrabbDPBunceC, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet2015; 385(9975): 1295–1304.
30.
De MoraesCGLiebmannJMLevinLA.Detection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma. Prog Retin Eye Res2017; 56: 107–147.
31.
KillerHEPircherA.Normal tension glaucoma: review of current understanding and mechanisms of the pathogenesis. Eye (Lond)2018; 32(5): 924–930.
32.
RotchfordAPKingAJ.Moving the goal posts definitions of success after glaucoma surgery and their effect on reported outcome. Ophthalmology2010; 117(1): 18–23.e3.
33.
HedmanKTaubeA.Which endpoint: mean intraocular pressure or proportion of successful patients?J Glaucoma2003; 12(4): 321–332.
34.
LesaffreE.Superiority, equivalence, and non-inferiority trials. Bull NYU Hosp Jt Dis2008; 66(2): 150–154.
35.
European Medicines Agency Committee for Medicinal Products for Veterinary Use (CVMP). Guideline on pharmaceutical fixed combination products. Report no. EMEA/CVMP/83804/05, 18December2006. London: European Medicines Agency.
36.
RobinAGroverDS.Compliance and adherence in glaucoma management. Indian J Ophthalmol2011; 59(Suppl.): S93–S96.
37.
MedeirosFA.Biomarkers and surrogate endpoints: lessons learned from glaucoma. Invest Ophthalmol Vis Sci2017; 58(6): BIO20–BIO26.
38.
Popa-CherechenauASchmidlDGarhoferG, et al. [Structural endpoints for glaucoma studies]. Ophthalmologe2019; 116: 5–13.
39.
IsmailRAzuara-BlancoARamsayCR.Consensus on outcome measures for glaucoma effectiveness trials: results from a delphi and nominal group technique approaches. J Glaucoma2016; 25(6): 539–546.
40.
Garway-HeathDFQuartilhoAPrahP, et al. Evaluation of visual field and imaging outcomes for glaucoma clinical trials (an American Ophthalomological Society Thesis). Trans Am Ophthalmol Soc2017; 115: T4.
41.
VillaniEMassaroDScaramuzziM, et al. Decade-long profile of imaging biomarker use in ophthalmic clinical trials. Invest Ophthalmol Vis Sci2017; 58(6): BIO76–BIO81.
42.
European Medicines Agency Committee for Medicinal Products for Human Use (CHMP). Guideline on the qualification and reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation. Report no. EMA/CHMP/458101/2016, 21July2016. London: European Medicines Agency.
LempMABaudouinCBaumJ, et al. The definition and classification of dry eye disease: report of the definition and classification Subcommittee of the International Dry Eye workshop (2007). Ocul Surf2007; 5: 75–92.
45.
UchinoMSchaumbergDA.Dry eye disease: impact on quality of life and vision. Curr Ophthalmol Rep2013; 1(2): 51–57.
46.
SongHZhangMHuX, et al. Correlation analysis of ocular symptoms and signs in patients with dry eye. J Ophthalmol2017; 2017: 1247138.
47.
JohnsonME.The association between symptoms of discomfort and signs in dry eye. Ocul Surf2009; 7(4): 199–211.
48.
BaudouinCAragonaPVanSettenG, et al. Diagnosing the severity of dry eye: a clear and practical algorithm. Br J Ophthalmol2014; 98(9): 1168–1176.
49.
SoriaJAceraAMerayo-LLovesJ, et al. Tear proteome analysis in ocular surface diseases using label-free LC-MS/MS and multiplexed-microarray biomarker validation. Sci Rep2017; 7(1): 17478.
50.
FogtJSKowalskiMJKing-SmithPE, et al. Tear lipid layer thickness with eye drops in meibomian gland dysfunction. Clin Ophthalmol2016; 10: 2237–2243.
51.
ChoHWolfKJWolfEJ.Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution. Clin Ophthalmol2009; 3: 199–210.
AssamJHBernhiselALinA.Intraoperative and postoperative pain in cataract surgery. Surv Ophthalmol2018; 63(1): 75–85.
54.
CoppensMVersichelenLMortierE.Treatment of postoperative pain after ophthalmic surgery. Bull Soc Belge Ophtalmol2002; 285: 27–32.
55.
Porela-TiihonenSKaarnirantaKKokkiM, et al. A prospective study on postoperative pain after cataract surgery. Clin Ophthalmol2013; 7: 1429–1435.
56.
LeeJTYatesWBRogersS, et al. Adalimumab for the treatment of refractory active and inactive non-infectious uveitis. Br J Ophthalmol2018; 102(12): 1672–1678.
57.
MurphyCCHughesEHFrostNA, et al. Quality of life and visual function in patients with intermediate uveitis. Br J Ophthalmol2005; 89(9): 1161–1165.
58.
Arriola-VillalobosPAbasoloLGarcia-FeijooJ, et al. Vision-related quality of life in patients with non-infectious uveitis: a cross-sectional study. Ocul Immunol Inflamm2018; 26(5): 717–725.
59.
Angeles-HanST.Quality-of-life metrics in pediatric uveitis. Int Ophthalmol Clin2015; 55(2): 93–101.
60.
KaleemunnishaSSudharshanSBiswasJ.Quality of life in non-infectious uveitis patients on immunosuppressive therapy. Middle East Afr J Ophthalmol2014; 21(3): 225–231.
61.
SheppardJJoshiABettsKA, et al. Effect of adalimumab on visual functioning in patients with noninfectious intermediate uveitis, posterior uveitis, and panuveitis in the VISUAL-1 and VISUAL-2 trials. JAMA Ophthalmol2017; 135(6): 511–518.
62.
DennistonAKKeanePASrivastavaSK.Biomarkers and surrogate endpoints in uveitis: the impact of quantitative imaging. Invest Ophthalmol Vis Sci2017; 58(6): BIO131–BIO140.
63.
TanACSTanGSDennistonAK, et al. An overview of the clinical applications of optical coherence tomography angiography. Eye (Lond)2018; 32(2): 262–286.
64.
European Medicines Agency. Similar biological medicinal products. Report no. CHMP/437/04 Rev. 1, 23October2014. London: European Medicines Agency.
65.
European Medicines Agency. Guideline on procedures for the granting of a marketing authorisation under exceptional circumstances, pursuant to Article 14 (8) of Regulation (EC) No 726/2004. Report no. EMEA/357981/2005, 15December2005. London: European Medicines Agency.
66.
BalasubramanianGMorampudiSChhabraP, et al. An overview of compassionate use programs in the European Union member states. Intractable Rare Dis Res2016; 5(4): 244–254.
67.
European Medicines Agency. Guideline on compassionate use of medicinal products, pursuant to Article 83 of Regulation (EC) No 726/2004. Report no. EMEA/27170/2006, 19July2007. London: European Medicines Agency.
68.
JewellNP.Natural history of diseases: statistical designs and issues. Clin Pharmacol Ther2016; 100(4): 353–361.
69.
NarendranNJaycockPJohnstonRL, et al. The Cataract National Dataset electronic multicentre audit of 55,567 operations: risk stratification for posterior capsule rupture and vitreous loss. Eye (Lond)2009; 23(1): 31–37.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
